Shared DNA methylation signatures in childhood allergy: The MeDALL study - 04/03/21
, Olena Gruzieva, MD, PhD f, g, ∗, Cancan Qi, MSc a, b, Ana Esplugues, PhD h, i, j, Ulrike Gehring, PhD k, Anna Bergström, PhD f, Dan Mason, PhD l, Leda Chatzi, MD, PhD m, Daniela Porta, MSc n, Karin C. Lodrup Carlsen, MD, PhD o, p, Nour Baïz, PhD q, Anne-Marie Madore, PhD r, Harri Alenius, PhD f, Bianca van Rijkom, BSc s, Soesma A. Jankipersadsing, MSc s, Pieter van der Vlies, BSc s, t, Inger Kull, PhD u, Marianne van Hage, MD, PhD v, w, Mariona Bustamante, PhD j, x, y, Aitana Lertxundi, PhD j, z, aa, Matias Torrent, MD, PhD bb, cc, Gillian Santorelli, MSc l, Maria Pia Fantini, MD dd, Vegard Hovland, MD, PhD p, Giancarlo Pesce, PhD q, the BIOS Consortium
Nanna Fyhrquist, PhD f, ee, Tiina Laatikainen, MD, PhD ff, gg, Martijn C. Nawijn, PhD b, hh, Yang Li, PhD c, d, e, Cisca Wijmenga, PhD s, Mihai G. Netea, MD, PhD e, ii, Jean Bousquet, MD, PhD jj, kk, Josep M. Anto, MD, PhD j, x, y, ll, Catherine Laprise, PhD r, mm, nn, Tari Haahtela, MD, PhD oo, Isabella Annesi-Maesano, MD, PhD q, Kai-Håkon Carlsen, MD, PhD o, p, Davide Gori, MD, PhD dd, Manolis Kogevinas, MD, PhD x, John Wright, FRCP l, Cilla Söderhäll, PhD pp, qq, Judith M. Vonk, PhD b, rr, Jordi Sunyer, MD, PhD j, x, y, ll, Erik Melén, MD, PhD u, ss, Gerard H. Koppelman, MD, PhD a, bAbstract |
Background |
Differential DNA methylation associated with allergy might provide novel insights into the shared or unique etiology of asthma, rhinitis, and eczema.
Objective |
We sought to identify DNA methylation profiles associated with childhood allergy.
Methods |
Within the European Mechanisms of the Development of Allergy (MeDALL) consortium, we performed an epigenome-wide association study of whole blood DNA methylation by using a cross-sectional design. Allergy was defined as having symptoms from at least 1 allergic disease (asthma, rhinitis, or eczema) and positive serum-specific IgE to common aeroallergens. The discovery study included 219 case patients and 417 controls at age 4 years and 228 case patients and 593 controls at age 8 years from 3 birth cohorts, with replication analyses in 325 case patients and 1111 controls. We performed additional analyses on 21 replicated sites in 785 case patients and 2124 controls by allergic symptoms only from 8 cohorts, 3 of which were not previously included in analyses.
Results |
We identified 80 differentially methylated CpG sites that showed a 1% to 3% methylation difference in the discovery phase, of which 21 (including 5 novel CpG sites) passed genome-wide significance after meta-analysis. All 21 CpG sites were also significantly differentially methylated with allergic symptoms and shared between asthma, rhinitis, and eczema. The 21 CpG sites mapped to relevant genes, including ACOT7, LMAN3, and CLDN23. All 21 CpG sties were differently methylated in asthma in isolated eosinophils, and 10 were replicated in respiratory epithelium.
Conclusion |
Reduced whole blood DNA methylation at 21 CpG sites was significantly associated with childhood allergy. The findings provide novel insights into the shared molecular mechanisms underlying asthma, rhinitis, and eczema.
Le texte complet de cet article est disponible en PDF.Key words : Epigenetics, DNA methylation, allergy, IgE, children
Abbreviations used : BIOS, EDEN, eQTM, EWAS, GWAS, INMA, MeDALL, NK, PIAMA, SNP
Plan
| The Mechanisms of the Development of Allergy (MeDALL) European Union project was supported by the Seventh Framework Programme (grant agreement 261357). The Biobank-Based Integrative Omics Studies (BIOS) Consortium was funded by BBMRI-NL, a research infrastructure financed by the Dutch government (NWO 184.021.007). Cohort-specific funding is described in the Online Supplement (at www.jacionline.org). The funders of the study had no role in design of the study, data gathering, analysis, interpretation, writing of the article, or in the decision to submit it for publication. M.G.N. was supported by a European Research Council Advanced Grant (833247) and a Spinoza Grant from The Netherlands Organization for Scientific Research. |
|
| Disclosure of potential conflict of interest: M. Hage reports personal fees from Thermo Fisher Scientific; ALK; Biomay AG, Vienna, Austria; and Hycor Biomedical LLC outside the submitted work. G. H. Koppelman participated in advisory board meetings for GSK and Pure-IMS outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 147 - N° 3
P. 1031-1040 - mars 2021 Retour au numéro
Article précédent
- A 300 IR sublingual tablet is an effective, safe treatment for house dust mite–induced allergic rhinitis: An international, double-blind, placebo-controlled, randomized phase III clinical trial
- Pascal Demoly, Jonathan Corren, Peter Creticos, Frédéric De Blay, Philippe Gevaert, Peter Hellings, Krzysztof Kowal, Martine Le Gall, Natalia Nenasheva, Giovanni Passalacqua, Oliver Pfaar, Miguel Tortajada-Girbés, Carmen Vidal, Margitta Worm, Thomas B. Casale
- Human milk oligosaccharide profiles and allergic disease up to 18 years
- Caroline J. Lodge, Adrian J. Lowe, Elasma Milanzi, Gayan Bowatte, Michael J. Abramson, Helen Tsimiklis, Christine Axelrad, Bianca Robertson, Aaron E. Darling, Cecilie Svanes, Matthias Wjst, Shyamali C. Dharmage, Lars Bode
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?